Dargahi N, Katsara M, Tselios T, Androutsou ME, De Courten M, Matsoukas J et al (2017) Multiple sclerosis: immunopathology and treatment update. Brain Sci 7(7):78

Article  PubMed  PubMed Central  Google Scholar 

McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA - J Am Med Assoc 325(8):765–779

Article  CAS  Google Scholar 

Cree BAC, Oksenberg JR, Hauser SL (2022) Multiple sclerosis: two decades of progress. Lancet Neurol [Internet]. [cited 2023 Nov 17];21(3):211–4. Available from: http://www.thelancet.com/article/S1474442222000400/fulltext

Momsen AMH, Ørtenblad L, Maribo T (2022) Effective rehabilitation interventions and participation among people with multiple sclerosis: an overview of reviews. Ann Phys Rehabil Med 65(1):101529

Article  PubMed  Google Scholar 

EBSCOhost | 162371560 | General overview about multiple sclerosis. [Internet]. [cited 2023 Nov 17]. Available from: https://web.s.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=09769234&AN=162371560&h=Jplz7M5VyMeLBafg%2bnxETz4%2bn3Mcej7zSfYzi8QsPgrWVzXVHfrSKKdT444EAwWdBIko9V3P5Zy1kb3Qb3JNlQ%3d%3d&crl=c&resultNs=AdminWebAuth&resultLocal=ErrCrlNotAuth&crlhashurl=login.aspx%3fdirect%3dtrue%26profile%3dehost%26scope%3dsite%26authtype%3dcrawler%26jrnl%3d09769234%26AN%3d162371560

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA et al (2019) The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 92(10):E1029–E1040

Article  PubMed  PubMed Central  Google Scholar 

Schoonheim MM, Broeders TAA, Geurts JJG (2022) The network collapse in multiple sclerosis: an overview of novel concepts to address disease dynamics. Neuroimage Clin 1(35):103108

Article  Google Scholar 

Hawton A, Goodwin E, Boddy K, Freeman J, Thomas S, Chataway J et al (2020) Measuring the cost-effectiveness of treatments for people with multiple sclerosis: beyond quality-adjusted life-years. https://doi.org/10.1177/1352458520954172 [Internet]. [cited 2023 Nov 17];28(3):346–51. Available from: https://journals.sagepub.com/doi/full/https://doi.org/10.1177/1352458520954172

Kołtuniuk A, Pytel A, Krówczyńska D, Chojdak-Łukasiewicz J (2022) The quality of life and medication adherence in patients with multiple sclerosis—cross-sectional study. Int J Environ Res Public Health 19:14549 [Internet]. 2022 Nov 5 [cited 2023 Nov 17];19(21):14549. Available from: https://www.mdpi.com/1660-4601/19/21/14549/htm

O’Gorman C, Lucas R, Taylor B (2012) Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 13(9):11718–11752

Article  PubMed  PubMed Central  Google Scholar 

Scalabrino G (2020) Epidermal growth factor in the CNS: a beguiling journey from integrated cell biology to multiple sclerosis. An extensive translational overview. Cell Mol Neurobiol 42:4 [Internet]. 2020 Nov 5 [cited 2023 Nov 17];42(4):891–916. Available from: https://link.springer.com/article/https://doi.org/10.1007/s10571-020-00989-x

Portaccio E, Amato MP (2022) Cognitive impairment in multiple sclerosis: an update on assessment and management. NeuroSci 3:667–676 [Internet]. 2022 Nov 22 [cited 2023 Nov 17];3(4):667–76. Available from: https://www.mdpi.com/2673-4087/3/4/48/htm

Guo A, Grabner M, Palli SR, Elder J, Sidovar M, Aupperle P et al (2016) Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis. ClinicoEconomics Outcomes Res 12(8):177–186

Google Scholar 

Palmer AJ, van der Mei I, Taylor BV, Clarke PM, Simpson S, Ahmad H (2020) Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: evidence from Australia. Mult Scler 26(4):411–420

Article  PubMed  Google Scholar 

Bebo B, Cintina I, Larocca N, Ritter L, Talente B, Hartung D et al (2022) The economic burden of multiple sclerosis in the United States. Neurology [Internet]. [cited 2023 Nov 18];98(18):e1810–7. Available from: https://n.neurology.org/content/98/18/e1810

Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler 26(14):1816–1821

Article  PubMed  PubMed Central  Google Scholar 

Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J (2017) New insights into the burden and costs of multiple sclerosis in Europe. Multe Scler J 23(8):1123–1136

Article  Google Scholar 

Rodríguez-Sánchez B, Daugbjerg S, Peña-Longobardo LM, Oliva-Moreno J, Aranda-Reneo I, Cicchetti A et al (2023) Does the inclusion of societal costs change the economic evaluation recommendations? A systematic review for multiple sclerosis disease. Eur J Health Econ [Internet]. [cited 2023 Nov 18];24(2):247–77. Available from: https://link.springer.com/article/https://doi.org/10.1007/s10198-022-01471-9

Koriem KMM (2016) Multiple sclerosis: new insights and trends. Asian Pacific J Trop Biomed 6(5):429–440

Article  CAS  Google Scholar 

Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132–1140

Article  PubMed  Google Scholar 

Ovchinnikov A, Findling O (2022) An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: immunotherapy with rituximab, ocrelizumab, and ofatumumab. Wiener Medizinische Wochenschrift [Internet]. [cited 2023 Nov 17];172(15–16):359–64. Available from: https://link.springer.com/article/https://doi.org/10.1007/s10354-022-00939-w

Lemus HN, Warrington AE, Rodriguez M (2018) Multiple sclerosis: mechanisms of disease and strategies for myelin and axonal repair. Neurol Clin 36(1):1–11

Article  PubMed  Google Scholar 

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372.

Grégoire G, Derderian F, Le Lorier J (1995) Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol [Internet]. [cited 2022 Apr 26];48(1):159–63. Available from: https://pubmed.ncbi.nlm.nih.gov/7853041/

Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M et al (2014) Budget impact analysis - principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value in health [Internet]. [cited 2022 Mar 27];17(1):5–14. Available from: http://www.valueinhealthjournal.com/article/S1098301513042356/fulltext

CHEERS Checklist Items to include when reporting economic evaluations of health interventions. [cited 2022 Apr 29]; Available from: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

ISPOR - Principles of Good Practice for Budget Impact Analysis II [Internet]. [cited 2023 Oct 28]. Available from: https://www.ispor.org/heor-resources/good-practices/article/principles-of-good-practice-for-budget-impact-analysis-ii

Soini E, Joutseno J, Sumelahti ML (2017) Cost-utility of first-line disease-modifying treatments for relapsing–remitting multiple sclerosis. Clin Ther 39(3):537-557.e10

Article  PubMed  Google Scholar 

Kantor D, Pham T, Patterson-Lomba O, Swallow E, Dua A, Gupte-Singh K (2023) Cost per relapse avoided for ozanimod versus other selected disease-modifying therapies for relapsing–remitting multiple sclerosis in the United States. Neurol Ther 12(3):849–861

Article  PubMed  PubMed Central  Google Scholar 

Dorman E, Kansal AR, Sarda S (2015) The budget impact of introducing delayed-release dimethyl fumarate for the treatment of relapse-remitting multiple sclerosis in Canada. J Med Econ 18(12):1085–1091

Article  PubMed  Google Scholar 

Bakhshai J, Bleu-Lainé R, Jung M, Lim J, Reyes C, Sun L et al (2010) The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ 13(1):63–69

Article  PubMed  Google Scholar 

Chiao E, Meyer K (2009) Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin 25(6):1445–1454

Article  CAS  PubMed  Google Scholar 

Silvestrini Viola C, Rojas JI, Patrucco L, Cristiano E, Elgart JF (2023) Analysis of the budget impact of incorporating alemtuzumab for the treatment of relapsing-remitting multiple sclerosis in Argentina. Neurologia Argentina 15(1):20–27

Article  Google Scholar 

Pastor-Quirós LJ, Correa-Díaz EP (2021) The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective. Glob Reg Health Technol Assess 8:140–146

PubMed  PubMed Central  Google Scholar 

Rosselli D, Guillermo Ariza J, Acosta T, Rueda JD (2012) Análisis de impacto presupuestal de la introducción de fingolimod en el tratamiento de esclerosis múltiple en Colombia: a budget impact analysis. Acta Neurológica Colombiana [Internet]. [cited 2023 Nov 4];28(1):4–10. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482012000100002&lng=en&nrm=iso&tlng=es

Aungsumart S, Turongkaravee S, Youngkong S, Apiwattanakul M, Thakkinstian A, Chaikledkaew U (2023) Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis. BMC Health Serv Res 23(1).

Matni M, Yamout B, Koussa S, Khamis C, Fleifel L, Sharifi S et al (2022) Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon. Mult Scler Relat Disord 1:67

Google Scholar 

Centonze D, Iannazzo S, Santoni L, Saleri C, Puma E, Giuliani L et al (2017) The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy. Mult Scler Demyelinating Disord 2(1).

Furneri G, Marchesi C, Santoni L (2016) Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy. Farmeconomia Health Econ Ther Pathways 17(1):29–39

Article  Google Scholar 

Cortesi PA, Paolicelli D, Capobianco M, Cozzolino P, Mantovani LG (2019) The value and sustainability of ocrelizumab in relapsing multiple sclerosis: a cost-effectiveness and budget impact analysis. Farmeconomia Health Econ Ther Pathways 20(1).

Cortesi PA, Antonazzo IC, Gasperini C, Nica M, Ritrovato D, Mantovani LG (2022) Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. PLoS One 17(3 March).

Mkrtchyan VR, Brylev LV, Davydova OV, Belyanin AV, Shpak IA, Sergeev AM (2015) Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis. Neurol Neuropsychiatry Psychosom 7(3):35–39

Article  Google Scholar 

Dee A, Hutchinson M, De La Harpe D (2012) A budget impact analysis of natalizumab use in Ireland. Ir J Med Sci 181(2):199–204

Article  CAS  PubMed  Google Scholar 

Schur N, Gudala K, Vudumula U, Vadapalle S, Bhadhuri A, Casanova A et al (2021) Cost effectiveness and budget impact of siponimod compared to interferon beta-1a in the treatment of adult patients with secondary progressive multiple sclerosis with active disease in Switzerland. Pharmacoeconomics 39(5):563–577

Article  PubMed  PubMed Central  Google Scholar 

Couto E, Folkehelseinstituttet (Norway). Medicines used for multiple sclerosis : a health technology assessment. 232

Sánchez-de la Rosa R, García-Bujalance L, Meca-Lallana J (2015) Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Econ Rev 5(1).

Sanchez-De La Rosa R, Casado MA (2013) Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain [Internet]. Available from: http://www.healtheconomicsreview.com/content/3/1/13

Sánchez de la Rosa R, Sabater E, Casado MA (2011) Análisis del impacto presupuestario del tratamiento en primera línea de la esclerosis múltiple remitente recurrente en España. Revista de neurología, ISSN 0210–0010, Vol 53, No 3, 2011, págs 129–138 [Internet]. [cited 2023 Nov 4];53(3):129–38. Available from: https://dialnet.unirioja.es/servlet/articulo?codigo=4504803&info=resumen&idioma=SPA

Zhang X, Hay JW (2014) Cost-Effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Value Health [Internet]. [cited 2023 Nov 19];17(3):A59–60. Available from: http://www.valueinhealthjournal.com/article/S1098301514004021/fulltext

Alsaqa’aby MF, Vaidya V, Khreis N, Al Khairallah T, Al-Jedai AH (2017) Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Ann Saudi Med [Internet]. [cited 2023 Nov 19];37(6):433–43. Available from: https://www.annsaudimed.net/doi/https://doi.org/10.5144/0256-4947.2017.433

Mantovani LG, Furneri G, Bitonti R, Cortesi P, Puma E, Santoni L et al (2019) Cost-effectiveness analysis of dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis: an Italian societal perspective. Farmeconomia Health economics and therapeutic pathways [Internet]. [cited 2023 Nov 19];20(1). Available from: http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1437/1782

gallehzan NA, Khosravi M, Soleimanpour S, Hoseini S, Mir H, Alipour V et al (2022) Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review. medRxiv [Internet]. [cited 2023 Nov 19];2022.08.10.22278518. Available from: https://www.medrxiv.or